From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence

• How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
• How are we are validating new, and assessing novel versus de-risked targets?
• What type of clinical data would lead the field to reassess assumptions on a target?

Speakers:

Ajla Hrle

Chief Business Officer

DISCO Pharmaceuticals GmbH

John Delyani

Chief Business Officer

Repertoire Immune Medicines

Helen Ho

Chief Business & Strategy Officer

Parabilis Medicines

Jordan Zwick

Chief Business Officer & Co-Founder

Mirador Therapeutics

Matthew Metzger

VP, US Ops

Oxford BioTherapeutics Ltd

Steve Bartz

Chief Business Officer

EpiBiologics